Open AccessThe Emerging Role of the SLCO1B3 Protein in Cancer Resistance
Author(s) -
Ruipu Sun,
Ying Ying,
Zhimin Tang,
Ting Liu,
Fuli Shi,
Huixia Li,
Taichen Guo,
Shibo Huang,
Ren Lai
Publication year - 2019
Publication title -
protein and peptide letters/protein and peptide letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 58
eISSN - 1875-5305
pISSN - 0929-8665
DOI - 10.2174/0929866526666190926154248
Subject(s) - camptothecin , prostate cancer , cancer , drug resistance , solute carrier family , chemotherapy , pharmacology , medicine , cancer research , colorectal cancer , transporter , lung cancer , cancer cell , abcg2 , biology , oncology , atp binding cassette transporter , biochemistry , gene , microbiology and biotechnology
Currently, chemotherapy is one of the mainstays of oncologic therapies. But the efficacy of chemotherapy is often limited by drug resistance and severe side effects. Consequently, it is becoming increasingly important to investigate the underlying mechanism and overcome the problem of anticancer chemotherapy resistance. The solute carrier organic anion transporter family member 1B3 (SLCO1B3), a functional transporter normally expressed in the liver, transports a variety of endogenous and exogenous compounds, including hormones and their conjugates as well as some anticancer drugs. The extrahepatic expression of SLCO1B3 has been detected in different cancer cell lines and cancer tissues. Recently, accumulating data indicates that the abnormal expression and function of SLCO1B3 are involved in resistance to anticancer drugs, such as taxanes, camptothecin and its analogs, SN-38, and Androgen Deprivation Therapy (ADT) in breast, prostate, lung, hepatic, and colorectal cancer, respectively. Thus, more investigations have been implemented to identify the potential SLCO1B3-related mechanisms of cancer drug resistance. In this review, we focus on the emerging roles of SLCO1B3 protein in the development of cancer chemotherapy resistance and briefly discuss the mechanisms of resistance. Elucidating the function of SLCO1B3 in chemoresistance may bring out novel therapeutic strategies for cancer treatment.